Abstract
Novel sulfa Schiff bases were synthesized and characterized by a reaction between aromatic sulfonamides and aromatic aldehydes or heterocyclic ketones in equimolar ratios. Their cytotoxicity was evaluated by the resazurin assay towards human sensitive CCRF-CEM and multidrug-resistant CEM/ADR5000 leukemia cells. Three of the tested compounds viz., 4-(anthracen-9-ylmethyleneamino)-N-(pyrimidin-2-yl)benzenesulfonamide (4), 4-(anthracen-9- ylmethyleneamino)benzenesulfonamide, (5) and 4-((3-phenylallylidene)amino)benzene-sulfonamide, (6) were cytotoxic (IC50 values: 5.38-19.96 µM). CEM/ADR5000 cells were not cross-resistant to these compounds, indicating activity against otherwise drug-resistant tumors. Compound 6 inhibited P-glycoprotein by increasing doxorubicin accumulation and reducing expression of P-glycoprotein in CEM/ADR5000 cells. A human P-glycoprotein homology model was used for molecular docking studies. Compound 6 and verapamil (a well-known P-glycoprotein inhibitor) docked with similar binding energies to the same binding pocket.
Keywords: Anthraldehyde, cancer, cinnamaldehyde, condensation, isatin, multidrug resistance, sulpha drugs, schiff bases.
Current Medicinal Chemistry
Title:Cytotoxicity of Novel Sulfanilamides Towards Sensitive and Multidrugresistant Leukemia Cells
Volume: 21 Issue: 23
Author(s): T. AlSalim, M.E.M. Saeed, J.S. Hadi, M. Zeino, R. Gany, O. Kadioglu, S.J.J. Titinchi, H.S. Abbo and T. Efferth
Affiliation:
Keywords: Anthraldehyde, cancer, cinnamaldehyde, condensation, isatin, multidrug resistance, sulpha drugs, schiff bases.
Abstract: Novel sulfa Schiff bases were synthesized and characterized by a reaction between aromatic sulfonamides and aromatic aldehydes or heterocyclic ketones in equimolar ratios. Their cytotoxicity was evaluated by the resazurin assay towards human sensitive CCRF-CEM and multidrug-resistant CEM/ADR5000 leukemia cells. Three of the tested compounds viz., 4-(anthracen-9-ylmethyleneamino)-N-(pyrimidin-2-yl)benzenesulfonamide (4), 4-(anthracen-9- ylmethyleneamino)benzenesulfonamide, (5) and 4-((3-phenylallylidene)amino)benzene-sulfonamide, (6) were cytotoxic (IC50 values: 5.38-19.96 µM). CEM/ADR5000 cells were not cross-resistant to these compounds, indicating activity against otherwise drug-resistant tumors. Compound 6 inhibited P-glycoprotein by increasing doxorubicin accumulation and reducing expression of P-glycoprotein in CEM/ADR5000 cells. A human P-glycoprotein homology model was used for molecular docking studies. Compound 6 and verapamil (a well-known P-glycoprotein inhibitor) docked with similar binding energies to the same binding pocket.
Export Options
About this article
Cite this article as:
AlSalim T., Saeed M.E.M., Hadi J.S., Zeino M., Gany R., Kadioglu O., Titinchi S.J.J., Abbo H.S. and Efferth T., Cytotoxicity of Novel Sulfanilamides Towards Sensitive and Multidrugresistant Leukemia Cells, Current Medicinal Chemistry 2014; 21 (23) . https://dx.doi.org/10.2174/0929867321666140120120708
DOI https://dx.doi.org/10.2174/0929867321666140120120708 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics (Review Article) Screening for Disease-Markers and Investigating Drug Effects by Proteome Profiling: Can it Meet Expectations?
Combinatorial Chemistry & High Throughput Screening Interaction Between Arsenic Trioxide and Human Primary Cells: Emphasis on Human Cells of Myeloid Origin
Inflammation & Allergy - Drug Targets (Discontinued) Ribozymes, DNAzymes and Small Interfering RNAs as Therapeutics
Current Drug Targets Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews Retinal Ganglion Cell Gene Therapy and Visual System Repair
Current Gene Therapy Recent Advances in Small Molecule Prodrugs for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Copper Compounds in Cancer Chemotherapy
Current Medicinal Chemistry Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Platelet Ca2+ATPases: Identification and Regulation in Hypertension
Current Hypertension Reviews Overview of Brain Tumor Stem Cells – Implications for Treatment
Current Signal Transduction Therapy Molecular Targeting of Protein Kinases to Optimize Selectivity and Resistance Profiles of Kinase Inhibitors
Current Topics in Medicinal Chemistry Novel Drug Targets in Malaria Parasite with Potential to Yield Antimalarial Drugs with Long Useful Therapeutic Lives
Current Pharmaceutical Design Gene Therapy in Fanconi Anemia: A Matter of Time, Safety and Gene Transfer Tool Efficiency
Current Gene Therapy An Evolving Role of Piperazine Moieties in Drug Design and Discovery
Mini-Reviews in Medicinal Chemistry Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Chemical and Genetic Engineering Strategies to Improve the Potency of Pharmaceutical Proteins and Enzymes
Current Medicinal Chemistry DNA and RNA Code-reading Molecules as Potential Gene Silencers in Neurobiology- What are They and what are They Good for?
Current Medicinal Chemistry - Central Nervous System Agents